About Alpenglow Biosciences
Alpenglow Biosciences is a private company based in Seattle, Washington. It has reported $7,982,788 raised in four offerings on Form D since January 2019. Its chief executive is Nicholas Reder.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 7, 2024 | Mar 25, 2024amended Dec 31, 2025 | $3,000,000fully sold | 14 | $214K | Debt, OptionsRule 506(b) | Form D/A ↗1 earlier filing |
| Jun 9, 2021 | Jun 22, 2021 | $4,582,788of $4.7M target | 11 | $416K | Equity, Securities on exerciseRule 506(b) | Form D ↗ |
| Sep 3, 2019 | Sep 10, 2019 | $300,000of $750K target | 2 | $150K | Debt, OptionsRule 506(b) | Form D ↗ |
| Dec 21, 2018 | Jan 7, 2019 | $100,000of $350K target | 2 | $50,000 | Debt, OptionsRule 506(b) | Form D ↗ |
| Total, four offerings | $7,982,788 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Alpenglow Biosciences's Form D filed Dec 31, 2025.
DK
Daniella Kranjac
Director
JL
Jonathan Liu
Director
NR
Nicholas Reder
Chief Executive Officer and director
MD
Michael Dutton
Executive officer
Earlier filings also listed Gustavo Mahler (director, last listed Jun 2021) and Steven Buckley (director, last listed Sep 2019).